Unravelling the true biopsychosocial impact of schistosomiasis.

Derick N M Osakunor, Sergi Alonso, Sandra Jumbe, Poppy H L Lamberton

Abstract readReview

In one paragraph

Review in Trends in parasitology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Derick N M OsakunorSchool of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK; Tackling Infections to Benefit Africa (TIBA) Partnership, University of Edinburgh, Edinburgh, UK. Electronic address: derick.osakunor@glasgow.ac.uk.

Sergi AlonsoSchool of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK; Global Business School for Health, University College London, London, UK.

Sandra JumbeSchool of Social and Health Sciences, Millennium University, Blantyre, Malawi; Centre for Evaluation and Methods, Wolfson Institute of Population Health, Barts, Queen Mary University of London, London, UK.

Poppy H L LambertonSchool of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schistosomiasis remains a debilitating parasitic disease, with over 200 million people infected globally. Heavy, chronic infections cause severe morbidity and over 12 000 deaths a year. As diagnostics improve, we have a greater understanding of more accurate prevalences. However, how infections, including light-intensity infections, affect individuals' health and quality of life remains to be fully understood, particularly as specific markers of morbidity, disease progression, and resolution are lacking. We explore evidence about the true broader physical, psychological, economic, social, and environmental impacts of schistosomiasis, identifying critical gaps in understanding the interplay between infection, morbidity, and wellbeing, and propose innovative approaches to better capture true long-term disease impacts. We argue for more holistic frameworks to inform disease monitoring, intervention evaluation, and policy development.

Indexed as

SchistosomiasisAnimalsHumansQuality of Lifebiopsychosocialeconomic burdenhealth-related quality of lifeimpactphysicalSchistosoma

Identifiers

PMID41956922

DOI10.1016/j.pt.2026.03.011

PMCPMC13201360

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.